Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The central nervous system (CNS) modulates pain through complex networks involving the periaqueductal gray (PAG), rostral ventromedial medulla (RVM), and other brain regions. This modulation relies on opioid and non-opioid mechanisms, descending pathways, and targets such as opioid receptors (mu, delta, kappa) and endogenous ligands like endorphins. Activation of these pathways can inhibit nociceptive transmission at the spinal level, providing analgesia. However, the system is complex, with potential for both inhibition and facilitation of pain, and is implicated in placebo analgesia and various chronic pain conditions.
Descending inhibition/disinhibition; bidirectional control of nociceptive transmission via opioidergic and non-opioidergic mechanisms in the PAG, RVM, and spinal cord. Activation of opioid receptors inhibits inhibitory interneurons, leading to enhanced suppression of ascending pain signals. Placebo analgesia also engages this circuitry.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Central Nervous System Analgesia via Modulation (CNS Analgesia).